Saturday 17 October 2026 Export OM’s income statement to Excel — free account

Outset Medical, Inc.

Outset Medical, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $119.5 million, up 5.09% from fiscal 2024. In the quarter to June 2026, revenue was flat, EPS grew 6.73%, free cash flow fell 90.5% and total debt rose 4.20%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years; insiders bought in the last twelve months.

3.94 0.14 −3.43%

Follow OM

Alert me

Market cap: $76.6M
P/E: 0.0×
Fwd P/E: −1.1×
Dividend yield: —
F-score: 6/9
Altman Z: −5.37
Beneish M: −3.25
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total buys 0.87

Total sells 0.37

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	1
Sell	3	1	6	3	—	—	3	1	—	3	—	—

Insider Ownership 4.99%

Capital & Financial Ratios $m

Market Cap 76.61

Revenue 117.80

Net Income (74.29)

Free Cash Flow (38.88)

Net Debt (48.40)

Current Ratio 5.19

Debt/Equity 1.03

P/E ratio 0.00

Fwd P/E (1.05)

P/S ratio 0.62

P/B ratio 0.76

Past 5Y EPS Growth —

This Y EPS Growth 28.29%

Next Y EPS Growth 25.62%

Next Y revenue growth 5.46%

Next 5Y EPS Growth 24.51%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 16.98%

10-year low 10-year high

P/B against its own 10 years 17.71%

10-year low 10-year high

EV/Sales against its own 10 years 7.11%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2025	Powerpack
2024	Powerpack
2023	Powerpack
2022	Powerpack
2021	Powerpack

predictions special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	203	159	169	147
Receivables	33	36	28	29
Inventory	49	59	48	47
Other	—	—	—	—
	291	258	251	228

	2023	2024	2025	Q'26
Payables	6	4	1	4
ST’ Debt	—	—	—	—
Other	—	—	—	—
	55	45	38	44

Compound Annual Growth %

	10y	5y	3y
Sales	—	19.06%	1.17%
Cash Flow	—	0.00%	0.00%
Earnings	—	0.00%	0.00%
Book Value	—	(17.32%)	(19.79%)

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	28	32	—	—	—
’25	30	31	29	29	119
’24	28	27	29	29	114
’23	33	36	30	31	130
’22	31	25	28	32	115
’21	23	25	26	28	103
’20	7	12	14	17	50

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(13)	(10)	—	—	—
’25	(26)	(5)	(6)	(10)	(46)
’24	(46)	(33)	(21)	(16)	(116)
’23	(45)	(28)	(34)	(24)	(131)
’22	(38)	(39)	(34)	(35)	(146)
’21	(39)	(31)	(28)	(33)	(130)
’20	(25)	(19)	(29)	(26)	(99)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(13)	(10)	—	—	—
’25	(26)	(5)	(6)	(10)	(47)
’24	(46)	(33)	(21)	(17)	(117)
’23	(46)	(29)	(35)	(25)	(135)
’22	(40)	(41)	(37)	(37)	(154)
’21	(40)	(32)	(29)	(34)	(133)
’20	(28)	(21)	(31)	(28)	(108)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(1.03)	(0.97)	—	—	—
’25	(3.66)	(1.04)	(1.00)	(1.09)	(5.37)
’24	(11.69)	(9.90)	(8.25)	(7.35)	(36.88)
’23	(13.49)	(13.49)	(13.94)	(11.54)	(52.17)
’22	(11.69)	(13.79)	(12.74)	(12.89)	(50.67)
’21	(10.49)	(9.90)	(9.75)	(13.04)	(43.33)
’20	(54.99)	(68.70)	(51.57)	(11.24)	(111.35)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	—	—	—	—	637.50	540.45	171.15	43.50	6.53	3.10	Analyst estimates 2026–2028 Powerpack
	High	—	—	—	—	1,004.40	915.00	730.65	458.25	88.20	25.35
People
People	Employees	—	—	—	273	313	444	518	480	354	310
	Revenue/emp, $m	—	—	0.00	0.06	0.16	0.23	0.22	0.27	0.32	0.39
Income, $m
Income, $m	Revenue	—	—	2	15	50	103	115	130	114	119
	Gross margin, %	—	—	(304.68)	(118.07)	(26.11)	7.42	15.46	22.24	33.92	39.13
	EBT	—	—	(50)	(68)	(121)	(132)	(163)	(172)	(127)	(81)
	EBT margin, %	—	—	(2,479.07)	(452.84)	(243.30)	(128.40)	(140.98)	(132.14)	(112.13)	(67.74)
	Net income	—	0	(50)	(68)	(121)	(132)	(163)	(173)	(128)	(82)
	Depreciation	—	—	0	1	3	7	6	(1)	1	2
Per share, $
Per share, $	Revenue	—	—	41.47	263.60	45.77	33.74	35.92	39.45	32.83	7.85
	Earnings	—	—	(1,029.42)	(1,193.44)	(111.35)	(43.33)	(50.67)	(52.17)	(36.88)	(5.37)
	Cash flow	—	—	(959.55)	(1,228.88)	(90.75)	(42.84)	(45.37)	(39.75)	(33.58)	(3.05)
	Capex	—	—	(36.49)	(57.57)	(8.32)	(1.02)	(2.59)	(1.04)	(0.26)	(0.05)
	Free cash flow	—	—	(996.03)	(1,286.45)	(99.07)	(43.86)	(47.96)	(40.79)	(33.85)	(3.10)
	Book value	—	—	0.00	651.38	301.17	123.02	76.58	37.18	7.74	8.35
	Shares, m	—	—	0	0	1	3	3	3	3	15
Valuation, ×
Valuation, ×	P/E	—	—	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	P/S	—	—	0.00	0.00	18.63	20.49	10.40	2.14	0.51	0.47
	P/B	—	—	0.00	0.00	2.83	5.62	4.88	2.28	2.15	0.44
	EV/Sales	—	—	0.00	0.00	12.94	17.48	8.75	1.59	0.86	(0.13)
	EV/FCF	—	—	(2.00)	(2.00)	(5.98)	(13.45)	(6.55)	(1.54)	(0.83)	0.32
Cash, $m
Cash, $m	Operating cash flow	—	—	(46)	(70)	(99)	(130)	(146)	(131)	(116)	(46)
	Capex	—	—	(2)	(3)	(9)	(3)	(8)	(3)	(1)	(1)
	Free cash flow	—	—	(48)	(74)	(108)	(133)	(154)	(135)	(117)	(47)
Balance, $m
Balance, $m	Working capital	—	—	137	55	309	358	322	236	213	213
	Total debt	—	—	29	29	30	30	96	130	197	96
	Net debt	—	—	(114)	(41)	(285)	(310)	(191)	(73)	39	(73)
	Shareholders’ equity	—	—	—	37	329	374	246	123	27	127
Returns, %
Returns, %	ROA	—	—	0.00	(193.43)	(32.23)	(30.42)	(37.74)	(48.41)	(43.41)	(30.23)
	ROIC	—	—	0.00	0.00	(169.11)	(126.76)	(183.56)	(213.60)	(108.17)	(76.86)
	ROE	—	—	22.14	25.89	364.06	(37.55)	(52.56)	(93.69)	(170.97)	(106.20)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
APYX Apyx Medical Corporation	$107.8M	— (loss-making)	— (loss-making)	+22.08% (above 0%: growing)	n/m	−137.38% (below 0%: shrinking)	63.89%	(13.01%)	Compare
LUCD Lucid Diagnostics Inc.	$105.7M	— (loss-making)	— (loss-making)	+26.74% (above 0%: growing)	n/m	−7.04% (below 0%: shrinking)	1.97%	(868.45%)	Compare
ZOMDF Zomedica Corp.	$95.4M	— (loss-making)	— (loss-making)	+36.59% (above 0%: growing)	n/m	+40.48% (above 0%: growing)	63.51%	(42.92%)	Compare
HYPR Hyperfine, Inc.	$82.7M	— (loss-making)	— (loss-making)	+44.81% (above 0%: growing)	n/m	+13.43% (above 0%: growing)	50.72%	(216.93%)	Compare
SERA Sera Prognostics, Inc.	$80.1M	— (loss-making)	— (loss-making)	+76.47% (above 0%: growing)	n/m	−10.58% (below 0%: shrinking)	(66.67%)	(33,346.67%)	Compare
LUNG Pulmonx Corporation	$79.5M	— (loss-making)	— (loss-making)	−4.62% (below 0%: shrinking)	n/m	−31.79% (below 0%: shrinking)	77.97%	(39.80%)	Compare
OM Outset Medical, Inc.	$76.6M	— (loss-making)	— (loss-making)	+0.69% (above 0%: growing)	n/m	−90.54% (below 0%: shrinking)	41.99%	(49.55%)
ECOR electroCore, Inc.	$75.3M	— (loss-making)	— (loss-making)	+28.03% (above 0%: growing)	n/m	−443.52% (below 0%: shrinking)	86.53%	(29.33%)	Compare
LNSR LENSAR, Inc.	$74.1M	2.0×	7.1×	+18.37% (above 0%: growing)	n/m	+96.81% (above 0%: growing)	59.27%	12.94%	Compare
Median of peers	$81.4M	—	—	+27.39%	—	−8.81%	61.39%	(41.36%)

All 149 Medical Devices stocks →

Outset Medical, Inc. (OM) key facts

Strength: Outset Medical, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $119.5 million, up 5.09% from fiscal 2024.
Outset Medical, Inc. (OM) is a Medical Devices company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, OM traded at $3.94, a market capitalization of $76.6 million.
Return on equity was −106.2% and debt-to-equity 1.03.
Its Piotroski F-score is 6 out of 9 and its Altman Z-score is −5.37 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.